Crouzon Syndrome - 24 Studies Found
Terminated |
: Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) : Medical Oncology : 2015-02-16 : Drug: BAY1187982 A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the start |
Recruiting |
: A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma : Advanced Cholangiocarcinoma : 2014-05-12 : Drug: BGJ398 Capsule for oral use |
Active, not recruiting |
: Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations : Solid Tumor : 2012-12-14 : Drug: ARQ 087 Subjects in this study will receive ARQ 087 orally at dose levels specified for their resp |
Recruiting |
: Dovitinib for Gastric Cancer With FGFR2 Amplification : Gastric Cancer : 2012-10-22 : Drug: Dovitinib
|
Recruiting |
: Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions :
: 2011-02-26 :
|
Not yet recruiting |
: Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer :
|
Recruiting |
: Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome :
|
Terminated |
: Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions :
|
Recruiting |
: Natural History of Craniofacial Anomalies and Developmental Growth Variants :
|
Completed |
: Clinical Trial of Fat Grafts Supplemented With Adipose-derived Regenerative Cells : Craniofacial Microsomia : 2012-08-22 :
|